“…Similarly, there was no statistically significant increase in mild (diarrhea, myalgia) to severe (ascites, spontaneous bacterial peritonitis, and variceal hemorrhage) adverse events. In five retrospective studies with cohort sizes of 343 to 40,512, no increase in adverse events or mortality was noted . Meta‐analysis shows that rather than worsening of liver function, there was a statistically significant improvement in disease progression and mortality …”